NA-Selank Amidate vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
NA-Selank Amidate
NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | NA-Selank Amidate | Cagrilintide |
|---|---|---|
| Mechanism | Same core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Intranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Primarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |